Accord Healthcare to file for global rights for critical drug LB-0702
Syna Therapeutics, a joint venture of Reig Jofre and Leanbio in Barcelona, has signed a global rights licensing deal with Ahmedabad-headquartered Intas Pharmaceuticals Ltd to commercialise its biosimilar drug LB-0702.
Under the terms of the agreement, Intas has been granted exclusive licensing rights to commercialize LB-0702 worldwide. Syna will develop and manufacture and supply LB-0702 to Intas and its worldwide affiliates.
As one of the key players in the global biosimilar market, Accord Healthcare, Intas’ wholly-owned subsidiary, has proven commercial capabilities with one of the largest sales and distribution networks in 85 countries globally.
Syna will begin clinical trials for LB-0702 in 2023 with support from its partners Leanbio and Reig Jofre. The company will utilise the technology platforms of Leanbio coupled with the technology production expertise of Reig Jofre at its new manufacturing plant in Barcelona, which is purposed for sterile injectables and lyophilised biopharmaceutical products.
“Signing this deal is one of Syna’s most important milestones since the company was founded in 2018. It confirms the pharmaceutical industry and healthcare systems’ growing interest in biosimilar drugs,” Dr Andreu Soldevila, co-founder and CEO of Syna, said on 4 Nov 2022.
“We are delighted with this agreement with Intas because we believe biosimilar LB-0702 will have a very positive impact on healthcare systems. Accord Healthcare, Intas’ wholly-owned subsidiary, is the ideal partner to commercialize our biosimilar in global markets. With this collaboration, we are committed to further strengthening the value of our biosimilar programs in global markets,” he added.
Binish Chudgar, Vice Chairman & Managing Director of Intas Pharmaceuticals, commented, “We are pleased to announce this agreement with Syna Therapeutics.
“This agreement sets out Accord Healthcare to file for global rights for this critical drug and is in line with our long-term strategy, reinforcing our commitment to improving access to high-quality biosimilar drugs for patients globally.”
Syna Therapeutics, founded in 2018, is a joint venture formed by Reig Jofre and Leanbio to develop high-quality biosimilars and innovative molecules to respond to the growing global demand for biological treatments.
Syna has extensive experience and know-how in all phases of biosimilar medicines, covering the entire value chain to enable biosimilars to reach patients: cell bank creation, pharma development of the finished product, industrial production, and marketing or license agreements.
Syna has its headquarters at the Barcelona Science Park.
Intas Pharmaceuticals Ltd is a leading vertically integrated pharmaceutical company, having end-to-end capabilities of formulation development, manufacturing and marketing along with backward integration of APIs. The organisation has more than 18,000 employees and 14 manufacturing sites worldwide and sells products in more than 85 countries.
Founded in 1929, Reig Jofre is a pharmaceutical company listed on the Spanish Stock Exchange market (RJF) dedicated to the R&D, manufacture and marketing of pharmaceutical products and food supplements. Its activity is structured into three business units: Pharmaceutical Technologies (sterile injectables, lyophilised products and antibiotics), Speciality Pharmacare (dermatology, osteoarticular, women’s health and paediatrics) and Consumer Healthcare (food supplements and OTC products).
Leanbio is a market-orientated Contract Development and Manufacturing Organisation (CDMO) that develops and manufactures biopharmaceutical products and new biological entities and biosimilars, using the Lean production and Quality by Design (QbD) approach to maximise success and cut time to market, costs and risks. Founded in 2014 by Dr Andreu Soldevila and Dr Albert Font, the company has four technology platforms and cutting-edge facilities at the Barcelona Science Park. fiinews.com
